Literature DB >> 2429439

Derivation of neutralizing monoclonal antibodies to human rotaviruses and evidence that an immunodominant neutralization site is shared between serotypes 1 and 3.

B S Coulson, J M Tursi, W J McAdam, R F Bishop.   

Abstract

Neutralizing monoclonal antibodies were derived to human rotaviruses RV-4 (serotype 1), RV-5 (serotype 2), and ST-3 (serotype 4). By enzyme immunoassay and fluorescent focus neutralization, eight of the antibodies appeared to be specific for the immunizing serotype, and so have potential as reagents for rotavirus serotyping by enzyme immunoassay. Seven of these were shown by Western blotting, enzyme immunoassay for antibody additivity, and reaction with rotavirus reassortants, to be directed against the major outer capsid glycoprotein. The remaining serotype-specific antibody immunoprecipitated the 84-kD outer capsid protein. One antibody reacted with all serotype 1 and 3 rotaviruses but not with serotypes 2 or 4. When tested with virus mutants, this antibody recognized an immunodominant determinant of neutralization shared between serotypes 1 and 3 on the major outer shell glycoprotein. Our results suggest that two outer capsid proteins possess determinants of neutralization, and that viruses of different serotypes may share immunodominant neutralization sites.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429439     DOI: 10.1016/0042-6822(86)90456-3

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  50 in total

1.  Comparisons of rotavirus VP7-typing monoclonal antibodies by competition binding assay.

Authors:  P Raj; D O Matson; B S Coulson; R F Bishop; K Taniguchi; S Urasawa; H B Greenberg; M K Estes
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Integrins alpha2beta1 and alpha4beta1 can mediate SA11 rotavirus attachment and entry into cells.

Authors:  M J Hewish; Y Takada; B S Coulson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals.

Authors:  D R Snodgrass; T A Fitzgerald; I Campbell; G F Browning; F M Scott; Y Hoshino; R C Davies
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

4.  Operational overlapping of cross-reactive and serotype-specific neutralization epitopes on VP7 of human rotavirus serotype 3.

Authors:  N Kobayashi; K Taniguchi; S Urasawa
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

5.  Epidemiology of rotavirus serotypes in Melbourne, Australia, from 1973 to 1989.

Authors:  R F Bishop; L E Unicomb; G L Barnes
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

6.  Relation of VP7 amino acid sequence to monoclonal antibody neutralization of rotavirus and rotavirus monotype.

Authors:  B S Coulson; C Kirkwood
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Rotavirus serotypes causing acute diarrhoea in hospitalized children in Yogyakarta, Indonesia during 1978-1979.

Authors:  R F Bishop; L E Unicomb; Y Soenarto; H Suwardji; G L Barnes
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

8.  Temporal and geographical distributions of human rotavirus serotypes, 1983 to 1988.

Authors:  G M Beards; U Desselberger; T H Flewett
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

9.  Epidemiology of symptomatic human rotaviruses in Bangalore and Mysore, India, from 1988 to 1994 as determined by electropherotype, subgroup and serotype analysis.

Authors:  S Aijaz; K Gowda; H V Jagannath; R R Reddy; P P Maiya; R L Ward; H B Greenberg; M Raju; A Babu; C D Rao
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

10.  Human rotavirus VP4 contains strain-specific, serotype-specific and cross-reactive neutralization sites.

Authors:  C D Kirkwood; R F Bishop; B S Coulson
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.